Clinical effect and safety of different maintenance doses of caffeine citrate in treatment of apnea in very low birth weight preterm infants: a prospective randomized controlled trial
ZHANG Xiao, ZHANG Hai-Tao, LYU Yong, WANG Li-Feng, YANG Zhen-Ying
Department of Neonatology, Tai'an Maternity and Child Care Hospital, Tai'an, Shandong 271000, China
Abstract：Objective To study the clinical effect and safety of different maintenance doses of caffeine citrate in the treatment of apnea in very low birth weight preterm infants. Methods A total of 78 very low birth weight preterm infants with primary apnea were enrolled who were admitted from January 2016 to January 2018. They were randomly divided into high-dose caffeine group with 38 children and low-dose caffeine group with 40 children. Both groups received a loading dose of 20 mg/kg caffeine citrate, and 24 hours later, the children in the high-dose caffeine group were given a maintenance dose of 10 mg/kg, and those in the low-dose caffeine group were given a maintenance dose of 5 mg/kg. The two groups were compared in terms of response rate and incidence rate of adverse events. Results The high-dose caffeine group had a significantly higher response rate than the low-dose caffeine group (71% vs 48%; P < 0.05). Compared with the low-dose caffeine group, the high-dose caffeine group had significantly shorter duration of apnea and time of caffeine treatment (P < 0.05). There were no significant differences between the two groups in length of hospital stay and incidence rates of tachycardia, feeding intolerance, bronchopulmonary dysplasia, necrotizing enterocolitis, and intracranial hemorrhage (P > 0.05). There was no significant difference in the mortality rate between the two groups (P > 0.05). Conclusions Higher maintenance dose of caffeine citrate has a better clinical effect than lower maintenance dose of caffeine citrate in the treatment of apnea in very low birth weight preterm infants, without increasing the incidence rates of adverse drug reactions and serious complications in preterm infants.
ZHANG Xiao,ZHANG Hai-Tao,LYU Yong et al. Clinical effect and safety of different maintenance doses of caffeine citrate in treatment of apnea in very low birth weight preterm infants: a prospective randomized controlled trial[J]. CJCP, 2019, 21(6): 558-561.
Schoen K, Yu T, Stockmann C, et al. Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity[J]. Paediatr Drugs, 2014, 16(2):169-177.
[10]
Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity[J]. N Engl J Med, 2007, 357(19):1893-1902.
[11]
Francart SJ, Allen MK, Stegall-Zanation J. Apnea of prematurity:caffeine dose optimization[J]. J Pediatr Pharmacol Ther, 2013, 18(1):45-52.
[12]
Mathew OP. Apnea of prematurity:pathogenesis and management strategies[J]. J Perinatol, 2011, 31(5):302-310.
[13]
Steer PA, Flenady V, Shearman A, et al. High dose caffeine citrate for extubation of preterm infants:a randomized controlled trial[J]. Arch Dis Child Fetal Neonatal Ed, 2004, 89(6):F499-F503.
